Overview

For small molecule drugs, the path to a marketed drug is arduous and because of its complexity, drug discovery and development is widely recognized as one of the most financially risky endeavors and a major challenge for the biomedical industry. The discovery and development process for biologics even more complexed path, and success is far from certain.
In recent times biologics too have attracted much attention primarily because the commercial potential of biologics is very promising and is delivering a better overall economic return than small molecule drugs.
Featured
Want to learn more about 2019 DIA-NIFDS Workshop: Science Based Drug Development and Approval? You've come to the right site!
Program Committee
-
Dong-Hee Lee Director General of Institute
MFDS, Korea, Republic of -
Kyung Won Seo Director General, National Institute of Food and Drug Safety Evaluation
Ministiry of Food and Drug Safety, Korea, Republic of -
Soojung Sohn, PhD Director General NIFDS
MFDS, Korea, Republic of -
Hae-Young Ahn, PhD President
Ahn Bio, United States -
Ho Jung Oh Director NIFDS
Ministry of Food and Drug Safety, Korea, Republic of -
SangAeh Park, PhD Director NIFDS
Ministry of Food and Drug Safety, Korea, Republic of -
Hojeong Kim Director NIFDS
MFDS, Korea, Republic of -
Jee Eun Lee, PhD Head of Research and Early Development
GC Pharma, Korea, Republic of
Have an account?